View Future GrowthKiora Pharmaceuticals 過去の業績過去 基準チェック /06Kiora Pharmaceuticalsは11.4%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.4%毎年増加している。売上は成長しており、年平均38.1%の割合である。主要情報11.35%収益成長率70.79%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率38.15%株主資本利益率-79.37%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新分析記事 • May 21Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They SeemShareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...Reported Earnings • Mar 28Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)Full year 2020 results: Net loss: US$8.09m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • May 04Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026. Location: 169 saxony road, suite 212, california 92024, encinitas United StatesNew Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.53m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Apr 07Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investorOn April 6, 2026, Kiora Pharmaceuticals, Inc. closed the transactionNew Risk • Mar 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.43m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$6.4m net loss in 3 years).New Risk • Nov 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.45m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years). Shareholders have been diluted in the past year (22% increase in shares outstanding).New Risk • Aug 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.10m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$8.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).New Risk • May 09New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: US$20k This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$9.36m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years).お知らせ • May 02Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025. Location: 169 saxony rd., suite 212, california 92024, encinitas, United StatesMajor Estimate Revision • Apr 01Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$2.50 to -US$2.99 per share. Revenue forecast of US$6.00m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 0.7% next year. Consensus price target of US$18.50 unchanged from last update. Share price fell 3.6% to US$2.93 over the past week.Price Target Changed • Jan 30Price target decreased by 39% to US$18.50Down from US$30.33, the current price target is an average from 2 analysts. New target price is 364% above last closing price of US$3.99. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$0.86 next year compared to a net loss per share of US$24.25 last year.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to US$3.91, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in the US. Total loss to shareholders of 98% over the past three years.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to US$3.90, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.Major Estimate Revision • Nov 15Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$0.887 to US$0.713 per share. Revenue forecast steady at US$16.5m. Net income forecast to shrink 252% next year vs 1.1% decline forecast for Pharmaceuticals industry in the US. Consensus price target of US$30.33 unchanged from last update. Share price fell 4.8% to US$3.40 over the past week.Price Target Changed • Nov 11Price target increased by 34% to US$40.50Up from US$30.33, the current price target is an average from 2 analysts. New target price is 984% above last closing price of US$3.74. Stock is down 32% over the past year. The company is forecast to post earnings per share of US$1.03 next year compared to a net loss per share of US$24.25 last year.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$4.04, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.83m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 37% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.83m market cap). Minor Risk Large one-off items impacting financial results.Major Estimate Revision • Aug 23Consensus EPS estimates increase by 64%, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.8m to US$16.5m. EPS estimate rose from US$0.54 to US$0.887. Net income forecast to shrink 188% next year vs 1.0% growth forecast for Pharmaceuticals industry in the US . Consensus price target of US$30.33 unchanged from last update. Share price was steady at US$3.77 over the past week.New Risk • Aug 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.98m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$3.67, the stock trades at a forward P/E ratio of 64x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.お知らせ • Jul 03Kiora Pharmaceuticals, Inc. Announces Board and Committee ChangesKiora Pharmaceuticals, Inc. announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board. Ms. Walters-Hoffert will serve as chair of the audit committee and as a member of the compensation committee. Concurrent with her appointment, Ken Gayron, current chair of the audit committee, will step down as a director of the Company's Board due to other work commitments. Ms. Walters-Hoffert was a co-founder of Dar Bioscience, Inc. and following the company's merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the resulting public company. For more than 25 years, Ms. Walters-Hoffert served as an investment banker focused on small-cap public companies in the life science and technology sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has also held various positions in the corporate finance and investment banking divisions of Citicorp Securities and Oppenheimer &Co, Inc. Ms. Walters-Hoffert currently serves as a director for Flux Power Holdings, Inc. and is a member of the Board of Directors of The Elementary Institute of Science. Additionally, she has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian's Advisory Board, and as the Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated magna cum laude from Duke University with a B.S. in Management Sciences.Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$4.92, the stock trades at a forward P/E ratio of 141x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.分析記事 • May 21Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They SeemShareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...お知らせ • Mar 26Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024, at 10:00 Pacific Standard Time. Location: 332 Encinitas Boulevard, Encinitas california United States Agenda: To consider elect two director nominees as Class III Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company's Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 150,000,000; and to consider other business matters.New Risk • Feb 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Market cap is less than US$100m (US$23.0m market cap).Price Target Changed • Feb 02Price target decreased by 69% to US$3.83Down from US$12.33, the current price target is an average from 3 analysts. New target price is 380% above last closing price of US$0.80. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$18.55 last year.New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (328% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.54m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years).Price Target Changed • Nov 13Price target increased by 42% to US$17.50Up from US$12.33, the current price target is an average from 2 analysts. New target price is 2,781% above last closing price of US$0.61. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.33 next year compared to a net loss per share of US$18.55 last year.お知らせ • Sep 22Kiora Pharmaceuticals, Inc. Announces Board ChangesSeptember 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors of Kiora Pharmaceuticals, Inc. from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date. Mr. Chaney did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Chaney’s retirement from the Board, as of the Effective Date, the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board. Additionally, the Board appointed Erin Parsons as Chair of the Compensation Committee of the Board, and appointed Carmine Stengone as a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, in each case effective as of the Effective Date.New Risk • Aug 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.6m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.06m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years).Price Target Changed • Aug 09Price target decreased by 56% to US$20.00Down from US$45.67, the current price target is an average from 2 analysts. New target price is 3,496% above last closing price of US$0.56. Stock is down 91% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$18.55 last year.お知らせ • Aug 02Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent DirectorKiora Pharmaceuticals, Inc. has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics. With the insights gained throughout his career and most recently from his time leading Pipeline, Stengone will positively impact guidance on strategic decision-making and further clinical development plans. In addition, his extensive network in the industry will help Kiora on multiple fronts. Stengone has served as President and Chief Executive Officer and as a director of Pipeline Therapeutics since 2018. In his role as CEO of Pipeline Therapeutics, he has completed three private rounds of financing totaling) $180 million and executed a)$1 billion collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson &Johnson. He also served as Senior Vice President, Business Development for COI Pharmaceuticals (now Avalon BioVentures Accelerator), and a member of its investment committee, where he helped co-found six new biopharmaceutical companies. While with Avalon Ventures, Carmine served as President and Chief Executive Officer of Avelas Biosciences, Inc. He also served as Vice President of Corporate Development for Afraxis Holdings, Inc. and co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Earlier in his career, he held positions of increasing responsibility with Phenomix Corporation, Anadys Pharmaceuticals, Inc., and Johnson &Johnson. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University and his M.S. and B.S degrees in chemistry from Duke University and Wake Forest University, respectively.お知らせ • Jul 23Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOn July 18, 2023, Kiora Pharmaceuticals, Inc. received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on January 15, 2024. In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common stock will become subject to delisting. In the event the Company receives notice that its common stock is being delisted, the Nasdaq Listing Rules permit the Company to appeal any such delisting determination by the Staff to a Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the Company will otherwise remain in compliance with the other listing standards for The Nasdaq Capital Market.Price Target Changed • May 12Price target increased by 39% to US$65.50Up from US$47.00, the current price target is an average from 2 analysts. New target price is 2,573% above last closing price of US$2.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.95 next year compared to a net loss per share of US$18.55 last year.お知らせ • Feb 16Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301In collaboration with Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital announced that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health. Currently enrolling a small group of RP patients, initial tests are currently being used to determine safety and tolerability of the experimental drug, as well as assessing whether patients have improved vision by evaluating their ability to identify objects, navigate through a mobility course and other ophthalmic and quality-of-life assessments. Also, the study is evaluating how the brain activity changes, specifically looking within the areas of image processing.お知らせ • Feb 08Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune DiseasesKiora Pharmaceuticals, Inc. announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. KIO-101 is part of a class of non-steroidal autoimmune disease drugs called DHODH inhibitors, which reduce T-cell proliferation and ongoing proinflammatory cytokine release. Approved systemic drugs in this class, which target systemic disease, generate about $2B in annual revenue. KIO-101 has the potential to affect the local immune response in the eye responsible for the ophthalmic signs and symptoms of these autoimmune diseases. Of the autoimmune diseases that KIO-101 is targeting, the ocular manifestations are found in approximately 3.43M patients in the U.S. The Phase 2 study of KIO-101 is a multicenter, randomized, controlled, double-masked clinical trial in up to 120 patients with ocular signs and symptoms and diagnosed autoimmune diseases, including RA, psoriatic disease, systemic lupus erythematosus, or fibromyalgia. The study will evaluate two concentrations of KIO-101, 0.15 % and 0.30 %. The efficacy endpoints will evaluate a number of established ocular signs and symptoms, including but not limited to corneal staining and changes in the Schirmer's test score at 12 weeks. The study will also evaluate several safety and tolerability measures.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Oct 13Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirementKiora Pharmaceuticals (NASDAQ:KPRX) has received a letter from Nasdaq on October 12, 2022 informing the company that it has regained compliance with the minimum bid price requirement. Kiora was previously notified by Nasdaq on February 23, 2022 that it was not in compliance with the minimum bid price rule.Seeking Alpha • Sep 26Kiora Pharma announces 1-for-40 reverse stock splitKiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a biotech focused on treatments for eye disorders, announced Monday that the company’s shareholders authorized a reverse stock split of the common stock. Accordingly, the KPRX board has approved a decision to implement a reverse stock split of one share of common stock for every 40 shares, and the company shares will begin trading on Nasdaq on a split-adjusted basis on Sep. 27. KPRX shares added ~10% pre-market after the announcement. The reverse stock split is expected to reduce KPRX’s total outstanding common shares to ~1.1M with no impact on authorized shares and par value which will remain at 50M and $0.01, respectively. Kiora (KPRX) shares have plunged ~90% over the past 12 months underperforming the broader maker, as shown in this graph.Board Change • Aug 17High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Aug 12Kiora Pharmaceuticals reports 1H resultsKiora Pharmaceuticals press release (NASDAQ:KPRX): 1H Net loss for the first half of 2022 was $6.0 million compared to $4.6 million for the first half of 2021. Cash and cash equivalents were $2.4 million as of June 30, 2022 with $1.1 million in prepaid expenses for research and development activities. Subsequent to the end of the first half, Kiora raised an additional $5.3 million in net proceeds from a public offering Shares +8.8% PM.Seeking Alpha • Jul 28Kiora gets US patent for KIO-201 use with antibiotics for eye wound healingKiora Pharmaceuticals (NASDAQ:KPRX) said it was granted a U.S. patent covering hydrogel-based sustained release platforms, including KIO-201, which helps in controlled release of antibiotics to treat eye diseases. The Salt Lake City-based company added that the patent — No. 11,376,214 — relates to non-blurring, antibiotic-containing hydrogel compositions which have an extended contact time on the eye and have potential to improve the health of the ocular surface for accelerated wound healing. Kiora noted that KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, formulated as an eye drop aimed to accelerate natural corneal wound healing. "In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections," said Kiora President and CEO Brian Strem.Seeking Alpha • Jul 22Kiora Pharmaceuticals prices $5.2M underwritten public offeringKiora Pharmaceuticals (NASDAQ:KPRX) prices an underwritten public offering for gross proceeds of ~$5.2M prior to deducting underwriting discounts and commissions and offering expenses. Underwriters' have a 45-day option to purchase up to ~3.93M additional shares. Closing expected to take place on or about July 26, 2022.Seeking Alpha • Jul 05Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201Kiora Pharmaceuticals (NASDAQ:KPRX) said it enrolled the first patient as a part of a phase 2 trial of its eye drops KIO-201 to treat patients with Persistent Corneal Epithelial Defect (PCED). PCED is a rare ocular surface condition characterized by non-healing wounds on the eye surface. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid aimed to accelerate natural corneal wound healing, according to the company's July 5 press release. The study will enroll 10 patients who will be evaluated at 28 days after receiving KIO-201 six times daily. The trial's goals are to evaluate safety and tolerability︎, and the percentage of patients with corneal healing and the associated time to healing.Breakeven Date Change • Jan 21No longer forecast to breakevenThe 3 analysts covering Kiora Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$38.8m in 2023. New consensus forecast suggests the company will make a loss of US$17.8m in 2023.Price Target Changed • Aug 17Price target decreased to US$11.83Down from US$13.25, the current price target is an average from 3 analysts. New target price is 622% above last closing price of US$1.64. Stock is down 66% over the past year.Executive Departure • Aug 05Director Steven Boyd has left the companyOn the 3rd of August, Steven Boyd's tenure as Director ended after 3.2 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Aug 05Director I. Maher has left the companyOn the 3rd of August, I. Maher's tenure as Director ended after 1.6 years in the role. We don't have any record of a personal shareholding under Maher's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering EyeGate Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$28.4m in 2022. New consensus forecast suggests the company will make a loss of US$3.90m in 2022.Price Target Changed • Apr 06Price target decreased to US$13.08Down from US$14.83, the current price target is an average from 3 analysts. New target price is 162% above last closing price of US$4.99. Stock is down 3.9% over the past year.Reported Earnings • Mar 28Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)Full year 2020 results: Net loss: US$8.09m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 05New 90-day high: US$7.30The company is up 121% from its price of US$3.30 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: US$6.63The company is up 70% from its price of US$3.89 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Price Target Changed • Dec 23Price target raised to US$12.83Up from US$11.50, the current price target is an average from 3 analysts. The new target price is 125% above the current share price of US$5.71. As of last close, the stock is down 34% over the past year.Is New 90 Day High Low • Dec 22New 90-day high: US$5.21The company is up 38% from its price of US$3.78 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%.Is New 90 Day High Low • Oct 29New 90-day low: US$3.57The company is down 18% from its price of US$4.34 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Price Target Changed • Sep 25Price target lowered to US$11.17Down from US$63.75, the current price target is an average from 3 analysts. The new target price is 206% above the current share price of US$3.65. As of last close, the stock is up 16% over the past year.収支内訳Kiora Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:KPRX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-116031 Dec 250-116030 Sep 250-96030 Jun 250-126031 Mar 250-126031 Dec 241646030 Sep 241665030 Jun 241635031 Mar 241625031 Dec 230-135030 Sep 230-136030 Jun 230-126031 Mar 230-127031 Dec 220-147030 Sep 220-177030 Jun 220-156031 Mar 220-156031 Dec 210-145030 Sep 210-95030 Jun 210-85031 Mar 210-75031 Dec 200-74030 Sep 200-84030 Jun 200-104031 Mar 200-104031 Dec 193-74030 Sep 193-74030 Jun 193-75031 Mar 193-85031 Dec 182-114030 Sep 182-114030 Jun 181-124031 Mar 181-134031 Dec 170-135030 Sep 171-145030 Jun 171-135031 Mar 171-145031 Dec 161-136030 Sep 161-126030 Jun 160-105031 Mar 160-85031 Dec 150-174030 Sep 150-1430質の高い収益: KPRXは現在利益が出ていません。利益率の向上: KPRXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: KPRXは利益を出していないが、過去 5 年間で年間11.4%の割合で損失を削減してきた。成長の加速: KPRXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: KPRXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: KPRXは現在利益が出ていないため、自己資本利益率 ( -79.37% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 23:17終値2026/06/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kiora Pharmaceuticals, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Keay NakaeChardan Capital Markets, LLCMichael OkunewitchMaxim Group
分析記事 • May 21Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They SeemShareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...
Reported Earnings • Mar 28Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)Full year 2020 results: Net loss: US$8.09m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 04Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026. Location: 169 saxony road, suite 212, california 92024, encinitas United States
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.53m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Apr 07Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investorOn April 6, 2026, Kiora Pharmaceuticals, Inc. closed the transaction
New Risk • Mar 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.43m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$6.4m net loss in 3 years).
New Risk • Nov 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.45m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years). Shareholders have been diluted in the past year (22% increase in shares outstanding).
New Risk • Aug 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.10m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$8.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • May 09New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: US$20k This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$9.36m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years).
お知らせ • May 02Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025. Location: 169 saxony rd., suite 212, california 92024, encinitas, United States
Major Estimate Revision • Apr 01Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$2.50 to -US$2.99 per share. Revenue forecast of US$6.00m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 0.7% next year. Consensus price target of US$18.50 unchanged from last update. Share price fell 3.6% to US$2.93 over the past week.
Price Target Changed • Jan 30Price target decreased by 39% to US$18.50Down from US$30.33, the current price target is an average from 2 analysts. New target price is 364% above last closing price of US$3.99. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$0.86 next year compared to a net loss per share of US$24.25 last year.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to US$3.91, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in the US. Total loss to shareholders of 98% over the past three years.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to US$3.90, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.
Major Estimate Revision • Nov 15Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$0.887 to US$0.713 per share. Revenue forecast steady at US$16.5m. Net income forecast to shrink 252% next year vs 1.1% decline forecast for Pharmaceuticals industry in the US. Consensus price target of US$30.33 unchanged from last update. Share price fell 4.8% to US$3.40 over the past week.
Price Target Changed • Nov 11Price target increased by 34% to US$40.50Up from US$30.33, the current price target is an average from 2 analysts. New target price is 984% above last closing price of US$3.74. Stock is down 32% over the past year. The company is forecast to post earnings per share of US$1.03 next year compared to a net loss per share of US$24.25 last year.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$4.04, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.
New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.83m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 37% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.83m market cap). Minor Risk Large one-off items impacting financial results.
Major Estimate Revision • Aug 23Consensus EPS estimates increase by 64%, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.8m to US$16.5m. EPS estimate rose from US$0.54 to US$0.887. Net income forecast to shrink 188% next year vs 1.0% growth forecast for Pharmaceuticals industry in the US . Consensus price target of US$30.33 unchanged from last update. Share price was steady at US$3.77 over the past week.
New Risk • Aug 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.98m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$3.67, the stock trades at a forward P/E ratio of 64x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years.
お知らせ • Jul 03Kiora Pharmaceuticals, Inc. Announces Board and Committee ChangesKiora Pharmaceuticals, Inc. announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board. Ms. Walters-Hoffert will serve as chair of the audit committee and as a member of the compensation committee. Concurrent with her appointment, Ken Gayron, current chair of the audit committee, will step down as a director of the Company's Board due to other work commitments. Ms. Walters-Hoffert was a co-founder of Dar Bioscience, Inc. and following the company's merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the resulting public company. For more than 25 years, Ms. Walters-Hoffert served as an investment banker focused on small-cap public companies in the life science and technology sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has also held various positions in the corporate finance and investment banking divisions of Citicorp Securities and Oppenheimer &Co, Inc. Ms. Walters-Hoffert currently serves as a director for Flux Power Holdings, Inc. and is a member of the Board of Directors of The Elementary Institute of Science. Additionally, she has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian's Advisory Board, and as the Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated magna cum laude from Duke University with a B.S. in Management Sciences.
Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$4.92, the stock trades at a forward P/E ratio of 141x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
分析記事 • May 21Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They SeemShareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...
お知らせ • Mar 26Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024, at 10:00 Pacific Standard Time. Location: 332 Encinitas Boulevard, Encinitas california United States Agenda: To consider elect two director nominees as Class III Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company's Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 150,000,000; and to consider other business matters.
New Risk • Feb 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Market cap is less than US$100m (US$23.0m market cap).
Price Target Changed • Feb 02Price target decreased by 69% to US$3.83Down from US$12.33, the current price target is an average from 3 analysts. New target price is 380% above last closing price of US$0.80. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$18.55 last year.
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (328% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.54m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years).
Price Target Changed • Nov 13Price target increased by 42% to US$17.50Up from US$12.33, the current price target is an average from 2 analysts. New target price is 2,781% above last closing price of US$0.61. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.33 next year compared to a net loss per share of US$18.55 last year.
お知らせ • Sep 22Kiora Pharmaceuticals, Inc. Announces Board ChangesSeptember 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors of Kiora Pharmaceuticals, Inc. from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date. Mr. Chaney did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Chaney’s retirement from the Board, as of the Effective Date, the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board. Additionally, the Board appointed Erin Parsons as Chair of the Compensation Committee of the Board, and appointed Carmine Stengone as a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, in each case effective as of the Effective Date.
New Risk • Aug 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.6m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.06m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years).
Price Target Changed • Aug 09Price target decreased by 56% to US$20.00Down from US$45.67, the current price target is an average from 2 analysts. New target price is 3,496% above last closing price of US$0.56. Stock is down 91% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$18.55 last year.
お知らせ • Aug 02Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent DirectorKiora Pharmaceuticals, Inc. has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics. With the insights gained throughout his career and most recently from his time leading Pipeline, Stengone will positively impact guidance on strategic decision-making and further clinical development plans. In addition, his extensive network in the industry will help Kiora on multiple fronts. Stengone has served as President and Chief Executive Officer and as a director of Pipeline Therapeutics since 2018. In his role as CEO of Pipeline Therapeutics, he has completed three private rounds of financing totaling) $180 million and executed a)$1 billion collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson &Johnson. He also served as Senior Vice President, Business Development for COI Pharmaceuticals (now Avalon BioVentures Accelerator), and a member of its investment committee, where he helped co-found six new biopharmaceutical companies. While with Avalon Ventures, Carmine served as President and Chief Executive Officer of Avelas Biosciences, Inc. He also served as Vice President of Corporate Development for Afraxis Holdings, Inc. and co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Earlier in his career, he held positions of increasing responsibility with Phenomix Corporation, Anadys Pharmaceuticals, Inc., and Johnson &Johnson. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University and his M.S. and B.S degrees in chemistry from Duke University and Wake Forest University, respectively.
お知らせ • Jul 23Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOn July 18, 2023, Kiora Pharmaceuticals, Inc. received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on January 15, 2024. In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common stock will become subject to delisting. In the event the Company receives notice that its common stock is being delisted, the Nasdaq Listing Rules permit the Company to appeal any such delisting determination by the Staff to a Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the Company will otherwise remain in compliance with the other listing standards for The Nasdaq Capital Market.
Price Target Changed • May 12Price target increased by 39% to US$65.50Up from US$47.00, the current price target is an average from 2 analysts. New target price is 2,573% above last closing price of US$2.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.95 next year compared to a net loss per share of US$18.55 last year.
お知らせ • Feb 16Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301In collaboration with Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital announced that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health. Currently enrolling a small group of RP patients, initial tests are currently being used to determine safety and tolerability of the experimental drug, as well as assessing whether patients have improved vision by evaluating their ability to identify objects, navigate through a mobility course and other ophthalmic and quality-of-life assessments. Also, the study is evaluating how the brain activity changes, specifically looking within the areas of image processing.
お知らせ • Feb 08Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune DiseasesKiora Pharmaceuticals, Inc. announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. KIO-101 is part of a class of non-steroidal autoimmune disease drugs called DHODH inhibitors, which reduce T-cell proliferation and ongoing proinflammatory cytokine release. Approved systemic drugs in this class, which target systemic disease, generate about $2B in annual revenue. KIO-101 has the potential to affect the local immune response in the eye responsible for the ophthalmic signs and symptoms of these autoimmune diseases. Of the autoimmune diseases that KIO-101 is targeting, the ocular manifestations are found in approximately 3.43M patients in the U.S. The Phase 2 study of KIO-101 is a multicenter, randomized, controlled, double-masked clinical trial in up to 120 patients with ocular signs and symptoms and diagnosed autoimmune diseases, including RA, psoriatic disease, systemic lupus erythematosus, or fibromyalgia. The study will evaluate two concentrations of KIO-101, 0.15 % and 0.30 %. The efficacy endpoints will evaluate a number of established ocular signs and symptoms, including but not limited to corneal staining and changes in the Schirmer's test score at 12 weeks. The study will also evaluate several safety and tolerability measures.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Oct 13Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirementKiora Pharmaceuticals (NASDAQ:KPRX) has received a letter from Nasdaq on October 12, 2022 informing the company that it has regained compliance with the minimum bid price requirement. Kiora was previously notified by Nasdaq on February 23, 2022 that it was not in compliance with the minimum bid price rule.
Seeking Alpha • Sep 26Kiora Pharma announces 1-for-40 reverse stock splitKiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a biotech focused on treatments for eye disorders, announced Monday that the company’s shareholders authorized a reverse stock split of the common stock. Accordingly, the KPRX board has approved a decision to implement a reverse stock split of one share of common stock for every 40 shares, and the company shares will begin trading on Nasdaq on a split-adjusted basis on Sep. 27. KPRX shares added ~10% pre-market after the announcement. The reverse stock split is expected to reduce KPRX’s total outstanding common shares to ~1.1M with no impact on authorized shares and par value which will remain at 50M and $0.01, respectively. Kiora (KPRX) shares have plunged ~90% over the past 12 months underperforming the broader maker, as shown in this graph.
Board Change • Aug 17High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Aug 12Kiora Pharmaceuticals reports 1H resultsKiora Pharmaceuticals press release (NASDAQ:KPRX): 1H Net loss for the first half of 2022 was $6.0 million compared to $4.6 million for the first half of 2021. Cash and cash equivalents were $2.4 million as of June 30, 2022 with $1.1 million in prepaid expenses for research and development activities. Subsequent to the end of the first half, Kiora raised an additional $5.3 million in net proceeds from a public offering Shares +8.8% PM.
Seeking Alpha • Jul 28Kiora gets US patent for KIO-201 use with antibiotics for eye wound healingKiora Pharmaceuticals (NASDAQ:KPRX) said it was granted a U.S. patent covering hydrogel-based sustained release platforms, including KIO-201, which helps in controlled release of antibiotics to treat eye diseases. The Salt Lake City-based company added that the patent — No. 11,376,214 — relates to non-blurring, antibiotic-containing hydrogel compositions which have an extended contact time on the eye and have potential to improve the health of the ocular surface for accelerated wound healing. Kiora noted that KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, formulated as an eye drop aimed to accelerate natural corneal wound healing. "In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections," said Kiora President and CEO Brian Strem.
Seeking Alpha • Jul 22Kiora Pharmaceuticals prices $5.2M underwritten public offeringKiora Pharmaceuticals (NASDAQ:KPRX) prices an underwritten public offering for gross proceeds of ~$5.2M prior to deducting underwriting discounts and commissions and offering expenses. Underwriters' have a 45-day option to purchase up to ~3.93M additional shares. Closing expected to take place on or about July 26, 2022.
Seeking Alpha • Jul 05Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201Kiora Pharmaceuticals (NASDAQ:KPRX) said it enrolled the first patient as a part of a phase 2 trial of its eye drops KIO-201 to treat patients with Persistent Corneal Epithelial Defect (PCED). PCED is a rare ocular surface condition characterized by non-healing wounds on the eye surface. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid aimed to accelerate natural corneal wound healing, according to the company's July 5 press release. The study will enroll 10 patients who will be evaluated at 28 days after receiving KIO-201 six times daily. The trial's goals are to evaluate safety and tolerability︎, and the percentage of patients with corneal healing and the associated time to healing.
Breakeven Date Change • Jan 21No longer forecast to breakevenThe 3 analysts covering Kiora Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$38.8m in 2023. New consensus forecast suggests the company will make a loss of US$17.8m in 2023.
Price Target Changed • Aug 17Price target decreased to US$11.83Down from US$13.25, the current price target is an average from 3 analysts. New target price is 622% above last closing price of US$1.64. Stock is down 66% over the past year.
Executive Departure • Aug 05Director Steven Boyd has left the companyOn the 3rd of August, Steven Boyd's tenure as Director ended after 3.2 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Aug 05Director I. Maher has left the companyOn the 3rd of August, I. Maher's tenure as Director ended after 1.6 years in the role. We don't have any record of a personal shareholding under Maher's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering EyeGate Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$28.4m in 2022. New consensus forecast suggests the company will make a loss of US$3.90m in 2022.
Price Target Changed • Apr 06Price target decreased to US$13.08Down from US$14.83, the current price target is an average from 3 analysts. New target price is 162% above last closing price of US$4.99. Stock is down 3.9% over the past year.
Reported Earnings • Mar 28Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)Full year 2020 results: Net loss: US$8.09m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 05New 90-day high: US$7.30The company is up 121% from its price of US$3.30 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: US$6.63The company is up 70% from its price of US$3.89 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Price Target Changed • Dec 23Price target raised to US$12.83Up from US$11.50, the current price target is an average from 3 analysts. The new target price is 125% above the current share price of US$5.71. As of last close, the stock is down 34% over the past year.
Is New 90 Day High Low • Dec 22New 90-day high: US$5.21The company is up 38% from its price of US$3.78 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%.
Is New 90 Day High Low • Oct 29New 90-day low: US$3.57The company is down 18% from its price of US$4.34 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Price Target Changed • Sep 25Price target lowered to US$11.17Down from US$63.75, the current price target is an average from 3 analysts. The new target price is 206% above the current share price of US$3.65. As of last close, the stock is up 16% over the past year.